


# ISGEDR

OSLO  
2025  
11-13 September

PROGRAM

---



# A NOTE FROM THE PRESIDENT & HOST

Dear Colleagues, Friends, and Guests,

On behalf of Oslo University Hospital, the University of Oslo, and the ISGEDR 2025 Organizing Committee, it is a pleasure to welcome you to the 2025 Meeting of the International Society for Genetic Eye Diseases & Retinoblastoma (ISGEDR), held in collaboration with the European Retinoblastoma Group (EURBG). We especially extend a warm welcome to our patient community, whose perspectives are an integral part of this event.

Over the next three days, we will explore developments in ophthalmic genetics and retinoblastoma through paper sessions, poster sessions, workshops, panel discussions, and symposiums. The program is designed to highlight the latest research, encourage the exchange of ideas, and foster collaboration between clinicians, scientists, and patient advocates from around the world.

Oslo, our host city, offers a unique backdrop for this meeting. Framed by forests, fjords, and a rich cultural heritage, it is a capital that balances modernity with tranquility. Whether you are here in person or joining virtually, we hope the program provides valuable insights and meaningful opportunities to connect.

We would like to express my sincere appreciation to the scientific & organizing committee, presenters, moderators, panelists, patient advocates, sponsors, and our AV & Data lead, Geoff Cross, for helping to shape this meeting. A special word of thanks goes to our event lead, Rachel Eilertsen, whose dedication and attention to detail have been essential in bringing ISGEDR 2025 together.

May these days be a time for sharing knowledge, strengthening collaboration, and expanding networks.

With warm regards,

Prof. hon. Dr.med Francis L. Munier  
President of ISGEDR

Dr Josephine Prener Holtan  
Program Chair, ISGEDR 2025

## HELD JOINTLY WITH



## OUR HOSTS



# COMMITTEE

## ORGANISING COMMITTEE

**Josephine Prener Holtan**, MD PhD,  
Local Lead Organizer and Program Chair

**Prof. hon. Dr.med Francis L. Munier**,  
President of ISGEDR

**Prof. Bart P Leroy**, MD, PhD,  
Executive Vice-President ISGEDR

**Prof. Elias I Traboulsi**, MD, MEd,  
Treasurer ISGEDR

**Rachel Eilertsen**, Event Lead, antVantage

**Geoff Cross**, Technical Lead, Avanddata

**Sandy Wong**, Administration, Cleveland  
Clinic

## SCIENTIFIC COMMITTEE

**Prof. hon. Dr.med Francis L. Munier**,  
President of ISGEDR, Retinoblastoma  
Consultant, Jules-Gonin Eye hospital,  
Faculty of Biology & Medicine, Lausanne  
University, Lausanne, Switzerland

**Prof. Bart P Leroy**, MD, PhD, Executive  
Vice- President ISGEDR, Ophthalmologist  
& Clinical Geneticist, Dept of  
Ophthalmology & Ctr for Medical Genetics,  
Ghent University Hospital, Ghent, Belgium

**Prof. Elias I Traboulsi**, MD, MEd, Treasurer  
ISGEDR, Stanley Stone Professor of  
Pediatric Ophthalmology & Ophthalmic  
Genetics Cole Eye Institute Cleveland  
Clinic, Cleveland, OH, USA  
**Prof. Ragnheiður Bragadóttir**, MD, PhD,  
Dept. of Ophthalmology, Oslo University  
Hospital, Institute of Clinical Medicine,  
Oslo University

**Josephine Prener Holtan**, MD PhD,  
Ophthalmic Genetics Consultant, Head  
of Electrophysiology Lab, Oslo University  
Hospital, Institute of Clinical Medicine,  
Oslo University, Oslo, Norway

**Marlies Hummelen**, MD, Retinoblastoma  
Consultant, Pediatric Ophthalmology,  
Dept of Ophthalmology, Oslo University  
Hospital

**Prof. Dr. med. Petra Ketteler**, Clinic for  
Pediatric Hematology and Oncology,  
University Hospital Essen, Essen,  
Germany, Chair (Ophthalmology) of the  
European Retinoblastoma Group (EURBG)

**M. Ashwin Reddy**, MA MBBChir MD  
(Res) FRCOphth, Consultant Paediatric  
Ophthalmologist, Lead clinician  
for Paediatric Ophthalmology &  
Retinoblastoma Services, Royal London  
Hospital, Barts Health NHS Trust,  
Undergraduate Lead for Ophthalmology,  
Royal London Hospital, QMUL, Honorary  
Consultant, Moorfields Eye Hospital NHS  
Foundation Trust, Chair (Ophthalmology)  
of the European Retinoblastoma  
Group (EURBG)

## MINI-SYMPPOSIA COMMITTEE

**Prof. Graeme Black**, Hon. Consultant  
in Genomics and Ophthalmology,  
Manchester Centre for Genomic  
Medicine. Professor of Genomics and  
Ophthalmology, School of Biological  
Sciences, Faculty of Biology, Medicine  
and Health, University of Manchester

**Prof. Mark Pennesi**, M.D., Ph.D.  
Director Ophthalmic Genetics, Retina  
Foundation. Professor of Ophthalmology,  
Molecular and Medical Genetics, Oregon  
Health & Science University US

**ISGEDR | OSLO 2025**

## SPONSORS

PLATINUM SPONSORS



**PYC**  
Therapeutics

GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSORS



Donations and support:

- The Research Council of Norway
- The Norwegian Retinitis Pigmentosa Patient Organization

## VENUES

DAY 1

### THURSDAY 11 SEPTEMBER

Meeting & Social at Storsalen, National Museum Oslo  
Address: Brynjulf Bulls plass 3, 0250 Oslo

DAY 2

### FRIDAY 12 SEPTEMBER

Meeting at Georg Sverdrup's House, Blindern, University of Oslo  
Address: Moltke Moes vei 39, 0851 Oslo

DAY 3

### SATURDAY 13 SEPTEMBER

Meeting at Georg Sverdrup's House, Blindern, University of Oslo  
Address: Moltke Moes vei 39, 0851 Oslo



Endorsed by:

- International Society of Paediatric Oncology
- International Society for Clinical Electrophysiology of Vision

# PROGRAM OVERVIEW

## THURSDAY 11 SEPTEMBER

NATIONAL MUSEUM, OSLO, STORSALEN

08:30 - 09:00	Registration
09:00 - 10:00	Opening Ceremony   Franceschetti Lecture
10:00 - 11:00	Award & Travel Grant Recipients   Ophthalmic Genetics 1
11:00 - 11:30	BREAK
11:30 - 12:30	Ophthalmic Genetics 1
12:30 - 13:30	LUNCH   Meet the sponsors
13:30 - 15:30	Cases
15:30 - 17:00	Social at the Museum
17:00 - 19:00	Free time
19:00 - 22:00	Mingle at Barcode Street Food*

\*Own expense

## FRIDAY 12 SEPTEMBER

UNIVERSITY OF OSLO, GEORG SVERDRUPS HOUSE

AUDITORIUM 1	AUDITORIUM 2
08:30 - 09:00	Registration
09:00 - 10:00	Ellsworth Lecture
10:00 - 11:00	Judith Kingston Lecture
	Retinoblastoma 1
11:00 - 11:30	BREAK   Poster session*
11:30 - 12:30	Ophthalmic Genetics 2
12:30 - 13:30	LUNCH   Meet the sponsors   12:45 ISGEDR Assembly (room 1)
13:30 - 15:30	Mini-symposium: Therapeutic innovation in IRD
	Retinoblastoma 2
	Retinoblastoma 3
15:30 - 16:00	BREAK   Poster session*
16:00 - 17:30	Ophthalmic Genetics 3
	Retinoblastoma 4
17:30 - 22:00	Dinner at Sporten**

\*Retinoblastoma 1 to 4 and Ophthalmic Genetics 1

\*\*Buses will transport attendees from the University of Oslo to the venue and back to the city center

## SATURDAY 13 SEPTEMBER

UNIVERSITY OF OSLO, GEORG SVERDRUPS HOUSE

AUDITORIUM 1	AUDITORIUM 2	ROOM 1
08:30 - 09:00	Registration	
09:00 - 10:00	Mini-symposium: Corneal Genetics, Diagnosis & Management	Retinoblastoma Workshop
10:00 - 11:00	Ophthalmic Genetics 4	
11:00 - 11:30	BREAK   Poster session*	
11:30 - 12:30	Francois Lecture	
12:30 - 13:30	LUNCH   Meet the sponsors Launch of third edition "Genetic Diseases of the Eye"	LUNCH (12:30 - 12:50)
13:30 - 14:30	Ophthalmic Genetics 5	EURBG Business Meeting (12:50-17:00)
14:30 - 15:30	Ophthalmic Genetics 6	
15:30 - 16:00	BREAK   Poster Session*	
16:00 - 17:00	Ophthalmic Genetics 7	IRD Patient Session
17:00 - 17:30	Closing Ceremony	EURBG Business Meeting

\*Ophthalmic Genetics Session 2 to 7

## PROGRAM



Scan for the latest updates and to download the full program.

### Paper sessions:



Please take a seat in the reserved section in the front of the room by the end of the break, just before your session. This will help us keep everything running smoothly and on time.



### Poster sessions:

All posters must be mounted between 08:30 - 08:50 on Friday, to ensure they are in place for the first session.

We kindly ask all presenters to be available at their posters during the allocated poster session times.

## NOTES







## CONTACTS

---

**Josephine Prener Holtan, MD PhD**  
Local Lead Organizer and Program Chair  
[jospree@ous-hf.no](mailto:jospree@ous-hf.no)

**Rachel Eilertsen**  
Event Lead, antVantage  
[rachel.antvantage@icloud.com](mailto:rachel.antvantage@icloud.com)

### Conflict of interest disclosure

The content of this meeting is independent of commercial interests. Any conflict of interest by the scientific organisers or the presenters will be disclosed in the related presentations and with the abstracts.